Prestige Consumer Healthcare (PBH) Current Assets (2011 - 2025)
Prestige Consumer Healthcare's (PBH) quarterly Current Assets came in at $433.4 million in Q4 2025, up 14.92% year-on-year from $377.2 million in Q4 2024, and down 12.86% quarter-over-quarter from $497.4 million in Q3 2025.
Prestige Consumer Healthcare (PBH) Current Assets (2011 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Current Assets history runs 15 years deep, the most recent figure standing at $433.4 million for Q4 2025.
- On a quarterly basis, Current Assets rose 14.92% year-over-year to $433.4 million in Q4 2025; TTM through Dec 2025 was $433.4 million, a 14.92% increase from a year earlier, with the FY2025 full-year figure at $448.3 million, up 19.54% from the prior year.
- Current Assets eased to $433.4 million in Q4 2025 per PBH's latest filing, from $497.4 million in the prior quarter.
- Across five years, Current Assets topped out at $497.4 million in Q3 2025 and bottomed at $269.8 million in Q1 2021.
- The 5-year median for Current Assets is $384.5 million (2023), against an average of $377.4 million.
- Across the five-year window, Current Assets decreased 26.2% in 2021 and soared 48.53% in 2022, its largest moves.
- Year by year, Current Assets stood at $275.3 million in 2021, then surged by 48.53% to $408.8 million in 2022, then slipped by 3.68% to $393.8 million in 2023, then declined by 4.22% to $377.2 million in 2024, then advanced by 14.92% to $433.4 million in 2025.
- Per Business Quant, the three latest PBH Current Assets figures stand at $433.4 million (Q4 2025), $497.4 million (Q3 2025), and $480.5 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 6.05 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.71 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 6.47 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 19.71 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 2.87 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 53.60 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 10.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.44 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.58 Bn |
| 10 | Prestige Consumer Healthcare | 2.34 Bn | 2.28 Bn | 157.37 Mn | 433.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 433.43 Mn |
| Sep 30, 2025 | 497.41 Mn |
| Jun 30, 2025 | 480.52 Mn |
| Mar 31, 2025 | 448.33 Mn |
| Dec 31, 2024 | 377.16 Mn |
| Sep 30, 2024 | 380.71 Mn |
| Jun 30, 2024 | 368.74 Mn |
| Mar 31, 2024 | 375.04 Mn |
| Dec 31, 2023 | 393.79 Mn |
| Sep 30, 2023 | 388.20 Mn |
| Jun 30, 2023 | 391.76 Mn |
| Mar 31, 2023 | 391.74 Mn |
| Dec 31, 2022 | 408.85 Mn |
| Sep 30, 2022 | 336.65 Mn |
| Jun 30, 2022 | 324.62 Mn |
| Mar 31, 2022 | 293.27 Mn |
| Dec 31, 2021 | 275.27 Mn |
| Sep 30, 2021 | 304.81 Mn |
| Jun 30, 2021 | 408.52 Mn |
| Mar 31, 2021 | 269.84 Mn |